Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Buy” from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $18.08.

A number of research firms have recently weighed in on ROIV. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th.

Insider Buying and Selling

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the sale, the chief operating officer now owns 896,869 shares in the company, valued at $9,551,654.85. This represents a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,388,170 shares of company stock worth $27,612,299. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Russell Investments Group Ltd. boosted its holdings in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after purchasing an additional 1,948 shares during the period. Gladius Capital Management LP bought a new stake in Roivant Sciences in the third quarter worth $35,000. US Bancorp DE boosted its stake in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences in the fourth quarter valued at $39,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $10.60 on Friday. The company has a market capitalization of $7.56 billion, a P/E ratio of -70.66 and a beta of 1.25. Roivant Sciences has a 1-year low of $9.76 and a 1-year high of $13.06. The firm’s 50 day simple moving average is $11.14 and its two-hundred day simple moving average is $11.60.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, sell-side analysts anticipate that Roivant Sciences will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.